Somatostatin, its receptors and analogs, in lung cancer

Kenneth J. O'Byrne, Andrew V Schally, Ann Thomas, Desmond N. Carney, William P. Steward

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201-995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1-5. Although elevated plasma somatostatin levels may be detected in 14-15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [111In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.

Original languageEnglish
Pages (from-to)78-108
Number of pages31
JournalChemotherapy
Volume47
Issue numberSUPPL. 2
DOIs
StatePublished - Apr 5 2001
Externally publishedYes

Fingerprint

Somatostatin Receptors
Somatostatin
Lung Neoplasms
Octreotide
Neoplasms
Bronchial Diseases
Neuroendocrine Cells
Lung
Immunomodulation
Small Cell Lung Carcinoma
Carcinoid Tumor
Therapeutics
North America
Tobacco Products
Synaptic Transmission
Radionuclide Imaging
Nervous System
Gastrointestinal Tract
Pancreas
Cause of Death

Keywords

  • [In]pentetreotide
  • Chemotherapy
  • Lung cancer
  • Receptor
  • Somatostatin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

O'Byrne, K. J., Schally, A. V., Thomas, A., Carney, D. N., & Steward, W. P. (2001). Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy, 47(SUPPL. 2), 78-108. https://doi.org/10.1159/000049163

Somatostatin, its receptors and analogs, in lung cancer. / O'Byrne, Kenneth J.; Schally, Andrew V; Thomas, Ann; Carney, Desmond N.; Steward, William P.

In: Chemotherapy, Vol. 47, No. SUPPL. 2, 05.04.2001, p. 78-108.

Research output: Contribution to journalArticle

O'Byrne, KJ, Schally, AV, Thomas, A, Carney, DN & Steward, WP 2001, 'Somatostatin, its receptors and analogs, in lung cancer', Chemotherapy, vol. 47, no. SUPPL. 2, pp. 78-108. https://doi.org/10.1159/000049163
O'Byrne KJ, Schally AV, Thomas A, Carney DN, Steward WP. Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy. 2001 Apr 5;47(SUPPL. 2):78-108. https://doi.org/10.1159/000049163
O'Byrne, Kenneth J. ; Schally, Andrew V ; Thomas, Ann ; Carney, Desmond N. ; Steward, William P. / Somatostatin, its receptors and analogs, in lung cancer. In: Chemotherapy. 2001 ; Vol. 47, No. SUPPL. 2. pp. 78-108.
@article{7fa175b32c2c4659a9c366159acf7186,
title = "Somatostatin, its receptors and analogs, in lung cancer",
abstract = "Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201-995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1-5. Although elevated plasma somatostatin levels may be detected in 14-15{\%} of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [111In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.",
keywords = "[In]pentetreotide, Chemotherapy, Lung cancer, Receptor, Somatostatin",
author = "O'Byrne, {Kenneth J.} and Schally, {Andrew V} and Ann Thomas and Carney, {Desmond N.} and Steward, {William P.}",
year = "2001",
month = "4",
day = "5",
doi = "10.1159/000049163",
language = "English",
volume = "47",
pages = "78--108",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Somatostatin, its receptors and analogs, in lung cancer

AU - O'Byrne, Kenneth J.

AU - Schally, Andrew V

AU - Thomas, Ann

AU - Carney, Desmond N.

AU - Steward, William P.

PY - 2001/4/5

Y1 - 2001/4/5

N2 - Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201-995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1-5. Although elevated plasma somatostatin levels may be detected in 14-15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [111In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.

AB - Despite developments in diagnosis and treatment, lung cancer is the commonest cause of cancer death in Europe and North America. Due to increasing cigarette consumption, the incidence of the disease and resultant mortality is rising dramatically in women. Novel approaches to the management of lung cancer are urgently required. Somatostatin is a tetradecapeptide first identified in the pituitary and subsequently throughout the body particularly in neuroendocrine cells of the pancreas and gastrointestinal tract and the nervous system. The peptide has numerous functions including inhibition of hormone release, immunomodulation and neurotransmission and is an endogenous inhibitor of cell proliferation and angiogenesis. Somatostatin and its analogs, including octreotide (SMS 201-995), somatuline (BIM 23014) and vapreotide (RC-160), act by binding to specific somatostatin receptors (SSTR) of which there are 5 principal subtypes, SSTR-1-5. Although elevated plasma somatostatin levels may be detected in 14-15% of patients, tumor cell expression appears rare. SSTR may be expressed by lung tumors, particularly small cell lung cancer and bronchial carcinoid disease. [111In]pentetreotide scintigraphy may have a role to play in the localization and staging of lung cancers both before and following treatment, and in detecting relapsed disease. The potential role of radiolabelled somatostatin analogs as radiotherapeutic agents in the management of lung cancer is currently being explored. Somatostatin analog therapy results in significant growth inhibition of both SSTR-positive and SSTR-negative lung tumors in vivo. Recent work indicates that these agents may enhance the efficacy of chemotherapeutic agents in the treatment of solid tumors including lung cancer.

KW - [In]pentetreotide

KW - Chemotherapy

KW - Lung cancer

KW - Receptor

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0035078136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035078136&partnerID=8YFLogxK

U2 - 10.1159/000049163

DO - 10.1159/000049163

M3 - Article

C2 - 11275704

AN - SCOPUS:0035078136

VL - 47

SP - 78

EP - 108

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - SUPPL. 2

ER -